Glaxosmithkline Intellectual Property Development Limited

Chroma Therapeutics Limited

Francesca Ann Day

Alan Hornsby Davidson

David Festus Charles Moffat

Alastair David Graham Donald

Alistair David Graham Donald

David Charles Festus Moffat

Sanjay Ratilal Patel

Alan Hastings Drummond

Andrew James Belfield

Compounds of formula (I) inhibit HDAC activity: wherein A, B and D independently represent &#x2550;C&#x2014; or &#x2550;N&#x2014;; W is a divalent radical &#x2014;CH&#x2550;CH&#x2014; or CHCH&#x2014;; Ris an ester group; Ris the side chain of a natural or non-natural alpha-amino acid; z is 0 or 1; and Y, L, and Xare as defined in the claims.

HDAC inhibitors

Compounds of formula (I) inhibit HDAC activity: wherein A, B and D independently represent &#x2550;C&#x2014; or &#x2550;N&#x2014;; W is a divalent radical &#x2014;CH&#x2550;CH&#x2014; or CHCH&#x2014;; Ris a carboxylic acid group (&#x2014;COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; Ris the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L, and Xare as defined in the claims.

Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate

Compounds of formula (I), and salts, N-oxides, hydrates and solvates thereof are histone deacetylase inhibitors and are useful in the treatment of cell proliferative diseases, including cancers: wherein Q, V and W independently represent &#x2014;N&#x2550; or &#x2014;C&#x2550;; B is a divalent radical selected from (B1), (B2), (B3), (B4), (B5) and (B6). wherein the bond marked * is linked to the ring containing Q, V and W through -[Linker1]- and the bond marked ** is linked to A through -[Linker2]-; A is an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system; -[Linker1]- and -[Linker2]- independently represent a bond, or a divalent linker radical; and R is (a) a radical of formula RRCHNH&#x2014;Y-L-X&#x2014;(CH)&#x2014; or (b) a radical of formula R-L-Y&#x2014;(CH)&#x2014;.

Hydroxamates as inhibitors of histone deacetylase

Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent &#x2550;C&#x2014; or &#x2550;N&#x2014;; W is a divalent radical &#x2014;CH&#x2550;CH&#x2014; or CHCH&#x2014;; Ris a carboxylic acid group (&#x2014;COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; Ris the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L, and Xare as defined in the claims. 

Growing community of inventors

Abingdon, United Kingdom

Francesca Ann Day